Results 191 to 200 of about 15,622,689 (344)
Review Of A Financial Revolution In The Habsburg Netherlands: Renten And Renteniers In The County Of Holland, 1515-1565 By J. D. Tracy [PDF]
DuPlessis, Robert S.
core +1 more source
Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson +2 more
wiley +1 more source
Pain in women: relevance of history of iron deficiency: comment on Laughey et al. (2025). [PDF]
Champion GD, Jaaniste T, Tan AC.
europepmc +1 more source
History and Modernity in Artistic Education from Romania [PDF]
Eugenia Maria Paşca
openalex +1 more source
Review Of The Cycles Of American History By A. M. Schlesinger Jr. [PDF]
Bannister, Robert C.
core +1 more source
Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia +9 more
wiley +1 more source
Dolphin bounty hunting in the history of the Italian fishery
Giorgio Bavestrello +3 more
openalex +2 more sources
Review Of A Colonial Lexicon Of Birth Ritual, Medicalization, And Mobility In The Congo By N. R. Hunt [PDF]
Burke, Timothy
core +2 more sources
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source

